Mainz Biomed N.V (MYNZ) said Tuesday it has partnered with Thermo Fisher Scientific (TMO) to develop a colorectal cancer screening test.
Financial details of the partnership were not disclosed.
Mainz said the partnership will combine its experience in mRNA-based colorectal cancer detection with Thermo Fisher's technology resources to develop a non-invasive test for detecting early-stage colorectal cancer and precancerous growths.
Shares of Mainz Biomed rose nearly 7% in recent Tuesday trading, while Thermo Fisher's rose 0.3%.
Price: 0.23, Change: +0.01, Percent Change: +6.51
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。